目的:探讨正常高值血压患者血管内皮功能变化及倍他乐克治疗的影响.方法:采用酶联免疫双抗体夹心法测定正常对照组(n=50)及正常高值血压组(n=100)倍他乐克治疗前后血清可溶性E选择素(sE-selectin)、血管性血友病因子(VWF)、可溶性细胞间黏附分子(sICAM-1)水平.结果:正常高值血压组较正常时照组存在高血清水平sE-selectin[(41.65±5.32)ng/nL vs (30.12±6.81)ng/nL,t=2.25,P<0.05]、VWF[(152.36±18.20)% vs (106.15±12.36)%,t=2.77,P<0.01]和sICAM-1[(225.12±27.12)μg/mL vs (155.73±16.34)μg/mL,t=2.63,P<0.01].经过4周倍他乐克治疗后,正常高值血压组患者sE-selectin[(41.65±5.32)ng/nLvs (34.15±6.10)ng/nL,t=2.01],VWF[(152.36±18.20)% vs (135.01±12.31)%,t=2.19],sICAM-1[(225.12±27.12)μg/mL vs (186.35±17.96)μg/mL,t=2.32]上述指标血清水平明显降低(P<0.05).结论:正常高值血压者存在血管内皮功能激活、受损,倍他乐克可改善正常高值血压患者血管内皮功能.